Fu Jin
Chongqing University
26 Papers
17 Citations
Fu Jin is an academic researcher from Chongqing University. The author has contributed to research in topics: Medicine & Radiation therapy. The author has an hindex of 4, co-authored 10 publications.
Chat about Author
Papers
Dosimetric comparison of helical tomotherapy, VMAT, fixed-field IMRT and 3D-conformal radiotherapy for stage I-II nasal natural killer T-cell lymphoma
Xian-Feng Liu,Erliang Huang,Ying Wang,Yanan He,Huanli Luo,Mingsong Zhong,Da Qiu,Chao Li,Han Yang,Guang-Lei He,Juan Zhou,Fu Jin +11 more
TL;DR: The unexpected results show that both HT and VMAT can achieve higher conformal treatment plans while getting worse organs at risk (OARs) sparing than IMRT for patients with Stage I-II NNKTL.
The role of image-guided radiotherapy in prostate cancer: A systematic review and meta-analysis
TL;DR: In this article , a meta-analysis showed that IGRT was associated with an improvement in biochemical tumor control and a reduction in GI and acute GU toxicity, but did not significantly improve 5-year prostate cancer patients or increase five-year SCM.
15
Cancer risk assessment in modern radiotherapy workflow with medical big data
Fu Jin,Huanli Luo,Juan Zhou,Yanan He,Xianfeng Liu,Mingsong Zhong,Han Yang,Chao Li,Qicheng Li,Xia Huang,Xiu-Mei Tian,Da Qiu,Guang-Lei He,Li Yin,Ying Wang +14 more
TL;DR: The cancer risk in modern RT workflow continues to be a problem and risk assessments based on the current knowledge of IGRT are developed and strategies for cancer risk reduction are provided.
Dose-time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer.
TL;DR: The options and problems related to both the dose–time fractionation schedule and time to surgery are discussed and the research questions that need answering in the future are addressed.
13
Gross Tumor Volume Segmentation for Stage III NSCLC Radiotherapy Using 3D ResSE-Unet
TL;DR: A 3D CNN model named 3D ResSE-Unet is proposed for gross tumor volume segmentation for stage III NSCLC radiotherapy and may be useful for lung cancer radiotherapy.
12